Chapter

Fungal Infection vs. Mold Allergy vs. Mycotoxin Toxicity

What It Really Means for You and Your Doctor

Yoon Hang Kim MD

Board Certified in Preventive Medicine

Integrative & Functional Medicine

Why This Chapter Matters

Few topics in medicine cause as much confusion as mold-related illness. Patients are confused. Doctors are confused. And a growing industry of unproven testing has made things worse.

Here is a common scenario. A patient comes in, whether in person or by telehealth, convinced that black mold in their home is slowly poisoning them. They have already paid hundreds of dollars for a urine mycotoxin test from a direct-to-consumer lab, and the result came back "positive." Now they want antifungal drugs, binders, and a detox protocol.

Down the hall sits a very different patient. This one's immune system is weakened after an organ transplant. They have a fever, a worsening cough, and new spots on a lung CT scan. This patient has a life-threatening fungal infection and needs antifungal medication started today.

Both patients have a "mold problem." Yet the two could not be more different. The difference comes down to a single word: mechanism, or how the illness actually works inside the body. Getting that right changes everything about how we diagnose and treat.

In Plain Language: If someone has told you that you have "mold toxicity" or "chronic mold illness," this chapter offers something more useful than a label. It will help you understand what is actually happening in your body, what testing can and cannot tell you, and how to have a clearer conversation with your doctor.

The Three Mechanisms

The same type of fungus can sometimes take part in all three of these processes. But the way each illness works, the way we test for it, and the way we treat it are completely different. Let's walk through them one at a time.

1. Fungal Infection: The Organism Is Growing Inside You

A fungal infection means a living fungus has taken hold somewhere in your body. It is not simply passing through your lungs as you breathe. It has settled in. It grows, it spreads, and in serious cases it invades your organs. Because a living organism is doing real damage, the evidence for infection should be concrete.

Who Gets Fungal Infections?

The single most important factor is how well your immune system is working.

The most dangerous type, called invasive fungal disease, mainly strikes people whose immune systems are severely weakened. That includes patients going through chemotherapy for blood cancers, those who have received an organ or stem-cell transplant, people on long-term high-dose steroids, and anyone whose white blood cell counts have dropped dangerously low, a condition called neutropenia.

A slower form, chronic pulmonary aspergillosis, usually appears in people who already have damaged lungs, whether from old tuberculosis, COPD, sarcoidosis, or a condition called bronchiectasis in which the airways are permanently widened. The fungus moves into spaces the lungs can no longer clear on their own.

Common surface infections such as athlete's foot, ringworm, and oral thrush can happen to healthy people. These are well understood and usually easy to treat.

Clinical Pearl: Breathing in mold spores, having mold in the house, or growing a fungus from a throat or sputum sample does not, by itself, mean a patient has an invasive infection. Mold is everywhere in the environment, and airway colonization, where the organism sits in the airway without invading tissue, is common. What matters is the whole picture: immune status, imaging, and how the patient is actually doing.

What Does Invasive Fungal Disease Look Like?

Invasive pulmonary aspergillosis, the most dangerous form, can cause a fever that does not respond to antibiotics, chest pain that worsens with breathing, cough, shortness of breath, and coughing up blood. A CT scan may show nodules or patches, sometimes ringed by a hazy "halo" of ground-glass opacity. In severe cases the infection spreads to the brain, kidneys, skin, and other organs.

The chronic form moves more slowly. Patients may lose weight, develop a lingering cough, cough up blood, and show holes, or cavities, forming in the lungs over months. An aspergilloma, a ball of fungus sitting inside an existing cavity, can cause significant bleeding.

Acute invasive fungal sinusitis is a medical emergency. It occurs mostly in patients with very low white blood cell counts or with uncontrolled diabetes complicated by ketoacidosis. Warning signs include facial pain or swelling, black scab-like tissue (an eschar) on the nose or roof of the mouth, facial nerve problems, and vision changes. This needs an ENT surgeon and infectious disease specialists immediately.

In Plain Language: If you are generally healthy, found mold at home, and started feeling tired, foggy, or achy, your symptoms are real and deserve attention. But an invasive fungal infection is extremely unlikely without a serious immune problem. Knowing that helps you and your doctor look in the right direction instead of the wrong one.

How Do We Diagnose Fungal Infection?

The testing should match how likely the diagnosis actually is. For high-risk patients, the Infectious Diseases Society of America (IDSA) recommends collecting tissue or fluid for both microscopic examination and culture. The main tools are these:

Imaging (CT or similar): looking for nodules, patches, cavities, or the classic halo sign.

Culture and tissue examination: growing the organism and looking at the tissue under a microscope. This is the gold standard when samples can be safely obtained.

Galactomannan testing (blood or lung fluid): galactomannan is a sugar released from the cell wall of growing Aspergillus. The test works best in high-risk patients such as those with blood cancers or transplants. It is not a screening tool for healthy people who happen to live near mold.

Beta-D-glucan: another cell-wall sugar found in many fungi. It offers a supporting clue but is not specific to any one species, and false positives are common.

Aspergillus IgG antibody: helpful for diagnosing chronic pulmonary aspergillosis when the imaging and clinical picture fit. It does not prove invasive infection, and it does not measure how much mold is in someone's home.

Clinical Pearl: A home mold plate, an environmental DNA test, a nonspecific antibody level, or a urine mycotoxin result does not establish a fungal infection. None of these can show whether a living organism is growing in tissue.

2. Mold Allergy: Your Immune System Is Overreacting

Mold allergy is a different story. Here the fungus is not growing inside you, and it does not even need to be alive. Dead spores and tiny fungal fragments can set off the reaction.

What happens is this. Your immune system mistakes certain mold proteins for a dangerous threat and makes an antibody called IgE against them. The next time you are exposed, your body launches an inflammatory response: sneezing, congestion, itching, watery eyes, coughing, wheezing. It is the same basic process behind pollen and pet-dander allergies.

The Typical Picture

Most mold allergy looks like other environmental allergies. Sneezing. A stuffy or runny nose. Itchy, watery eyes. Cough. Wheezing. Sometimes worsening eczema. The telling clue is timing: symptoms flare during or shortly after exposure and ease once you leave the environment.

Dampness and visible mold can also irritate the nose, throat, and eyes in people who have no true allergy at all. That is why fixing the water problem and removing the mold matters regardless of what any test shows.

How Do We Diagnose Mold Allergy?

A solid diagnosis needs four pieces working together:

1. The right symptoms. The person genuinely has allergy-type complaints, not just fatigue or brain fog.

2. A believable exposure pattern. Symptoms come and go with mold exposure in a way that makes sense.

3. Proof of sensitization. A skin-prick test or blood test (specific IgE) shows the immune system recognizes the mold.

4. Improvement with treatment. Symptoms ease when exposure drops or standard allergy treatment begins.

Clinical Pearl: A positive skin test or specific IgE proves only sensitization: the immune system has met the mold and made antibodies against it. It does not prove the mold is causing today's symptoms. Many people test positive for mold without any symptoms at all. Testing should follow the patient's actual exposures, not arrive as a giant shotgun panel. And mold-specific IgG is the wrong test for ordinary mold allergy.

In Plain Language: Think of it this way. A positive allergy test means your immune system recognizes a certain mold. It does not prove that mold is why you feel bad right now. Your doctor still has to connect the dots: the right symptoms, at the right time, easing with the right treatment. That is what separates a real allergy diagnosis from a lab number that means little on its own.

ABPA: Where Allergy and Colonization Overlap

Allergic bronchopulmonary aspergillosis, or ABPA, sits between infection and allergy. Aspergillus colonizes the airways, meaning it lives and grows there, but the main problem is not tissue invasion. The main problem is that the immune system overreacts to the fungus with a large inflammatory response.

ABPA usually appears in people who already have asthma, cystic fibrosis, or bronchiectasis. It can cause thick mucus plugs, recurring patches on chest imaging, and, if missed, permanent airway damage.

The 2024 international guidelines (ISHAM) call for proof that the immune system is sensitized to the fungus, a total IgE blood level of at least 500 IU/mL, and at least two of the following: elevated Aspergillus-specific IgG, a high count of eosinophils (a white blood cell involved in allergic reactions), or imaging that fits the pattern.

Hypersensitivity Pneumonitis: An Immune Lung Disease

Hypersensitivity pneumonitis (HP) is another condition that resists easy labeling. It is an immune-driven lung disease caused by breathing in a trigger over and over. That trigger can be mold, but it can also be bird proteins, bacteria, or certain chemicals.

HP causes cough, worsening shortness of breath, low oxygen, and imaging changes that look like interstitial lung disease, a pattern of inflammation and scarring in the tissue between the air sacs.

Diagnosing it takes teamwork: a detailed history of what the patient has been breathing in at home, at work, and through hobbies; a high-resolution CT scan; lung function tests; and sometimes bronchoalveolar lavage (washing fluid into and out of the lungs to sample it) or a lung biopsy.

A blood test showing IgG antibodies to a particular antigen can confirm that exposure happened. It cannot, on its own, prove the exposure caused the disease. IgG positivity means the immune system has met the antigen. It does not prove the antigen is making the patient sick.

3. Mycotoxin Toxicity: Where Science Ends and Marketing Begins

This is where the conversation gets heated, and where clear thinking matters most.

Mycotoxins are real. They are small toxic chemicals that certain molds produce under certain conditions. Mycotoxin poisoning, called mycotoxicosis, is real too. The question is not whether mold chemicals can harm people. The question is when, and under what conditions, they actually do.

What We Know for Sure

Not every mold makes mycotoxins. Even a species that can produce them is not necessarily doing so at any given moment. Finding a toxin-capable mold in a building does not prove that toxins are being made, that anyone absorbed a harmful dose, or that anyone got sick from them.

The best-proven route of human exposure is food. Acute aflatoxin poisoning from contaminated grain can cause severe, sometimes fatal, liver damage, and long-term aflatoxin exposure is a known risk factor for liver cancer, especially where food-safety monitoring is limited. The FDA actively screens the food supply for several mycotoxins, including aflatoxins and fumonisins.

Very heavy occupational exposure, such as working in a grain silo full of moldy dust, can cause a short-term inflammatory illness called organic dust toxic syndrome. This is a genuine condition, but it involves massive exposure levels, nothing like what someone meets in a damp apartment or a moldy bathroom.

What Has Not Been Proven

Here honesty matters more than popularity.

Several major medical organizations have reviewed the evidence, and they reach the same conclusion. The American College of Medical Toxicology (ACMT), the American Academy of Allergy, Asthma & Immunology (AAAAI), and the 2023 AWMF international guideline all agree: there is no convincing evidence that breathing in mycotoxins at the levels found in ordinary damp homes and offices causes chronic, whole-body illness.

The cluster of symptoms often called "toxic mold syndrome" or "chronic inflammatory response syndrome" (CIRS), including fatigue, brain fog, joint pain, headaches, poor sleep, and digestive complaints, has not been shown to result from indoor mold at normal residential levels.

This does not mean damp buildings are safe. They clearly worsen respiratory and allergic disease, and they should be fixed. But "damp buildings cause breathing problems" is a very different claim from "ordinary indoor mold causes chronic whole-body poisoning." The evidence supports the first. It does not support the second.

The studies claiming chronic indoor mycotoxicosis tend to share the same weaknesses: no proper control groups, no objective measurement of how much toxin people absorbed, no established threshold for what dose causes disease, and no blinded assessment.

Clinical Pearl: Calling chronic whole-body illness from ordinary indoor mold "well established" goes beyond what the evidence shows. Clinicians should stay open to new data as it emerges. They also owe patients an honest picture of where the science stands today.

In Plain Language: If you have been living with mold and feeling terrible, your suffering is real, and your symptoms deserve a thorough workup. What the evidence suggests is that the cause may not be systemic mycotoxin poisoning, and that chasing that diagnosis through unproven tests can lead you away from the real answer rather than toward it.

The Testing Problem

Urine Mycotoxin Panels: What They Actually Tell You

Urine mycotoxin panels have become a booming business. Labs market them straight to patients and practitioners as a way to diagnose "mold toxicity." Here is what you need to know.

The CDC has stated plainly that low levels of mycotoxins turn up in the urine of healthy people, largely because food is a common source. There are no established thresholds separating a "normal" level from a "disease" level, and there is no FDA-approved urine mycotoxin test for diagnosing illness.

Many of these labs advertise that they are CLIA-certified. CLIA certification means a lab follows quality standards and measures what it claims to measure with reasonable accuracy. It does not mean the test itself is clinically useful for diagnosing disease. A lab can be fully certified and still offer a test that yields no actionable information.

A "positive" urine mycotoxin result cannot tell you:

Where the exposure came from. Your morning coffee or last night's peanut butter can account for it, not your bathroom.

When it happened. These are breakdown products being filtered out, not timestamps.

Whether the level is truly abnormal. Without norms for healthy people, "detectable" is not the same as "dangerous."

Whether the mycotoxin caused your symptoms. Finding a substance and having symptoms at the same time does not prove one caused the other.

Whether a falling level means you are recovering. If the starting number was never meaningful, neither is the trend.

Clinical Pearl: Both the ACMT and the 2023 AWMF guideline advise against blood or urine mycotoxin testing to evaluate indoor mold exposure. Ordering these tests and then treating the results as a confirmed diagnosis creates a self-reinforcing loop that does not help patients find real answers.

Antibody Tests: What IgE and IgG Really Mean

Mold-specific IgE is useful when it matches the clinical picture. In a patient with allergy symptoms and a believable exposure history, a positive IgE to a relevant mold helps confirm the diagnosis. This is standard allergy practice.

Mold-specific IgG is useful in specific conditions: hypersensitivity pneumonitis, ABPA, and chronic pulmonary aspergillosis. There it signals meaningful immune contact with the fungus. It is not a general "mold toxicity" marker, and it is not the right test for ordinary mold allergy.

Mycotoxin antibodies have not been validated for measuring exposure or diagnosing toxicity. Some labs offer them anyway, but the clinical evidence simply is not there.

Total IgE is a nonspecific number. It becomes useful inside defined conditions such as ABPA, where a level of at least 500 IU/mL is one criterion. On its own, a high total IgE does not diagnose "mold illness."

Environmental Testing: What It Can and Cannot Do

If you can see mold or smell a musty odor, you have a moisture problem that needs fixing. That part is simple.

The CDC does not recommend routine mold sampling in homes. No health-based indoor standard reliably turns a spore count into a specific disease risk for a specific person, and the fix, correcting the moisture and removing the mold, is the same regardless of species.

Environmental testing can help locate the moisture source, gauge how far the damage extends, and plan the cleanup, especially in workplaces or institutions. What it generally cannot do is diagnose an individual's infection, allergy, or toxicity. Finding a particular species on your wall does not tell you whether it is producing toxins, whether you absorbed a harmful dose, or whether your fatigue has anything to do with it.

A Step-by-Step Approach for Clinicians

When a patient says their symptoms come from mold, here is a practical way to work through the evaluation.

Step 1: Figure Out the Symptom Pattern

Runny nose, sneezing, itchy eyes, episodic wheezing, eczema: think allergic disease and irritant exposure, and start with a focused allergy workup.

Asthma plus recurring lung infiltrates, mucus plugging, high eosinophils, or very high IgE: think ABPA, and apply the 2024 ISHAM criteria.

Worsening shortness of breath, low oxygen, crackles, a restrictive pattern, or interstitial lung disease on imaging: think hypersensitivity pneumonitis. Get an exposure history, a high-resolution CT, lung function tests, and consider BAL or biopsy.

Fever, lung nodules or infiltrates, cavities, coughing up blood, or dying tissue in a patient with a weakened immune system: think invasive fungal infection. This is urgent. Get imaging, cultures, tissue, and antigen testing right away.

Weight loss, chronic cough, blood in the sputum, and progressive lung cavities over three or more months in someone with damaged lungs: think chronic pulmonary aspergillosis, and rule out tuberculosis, nontuberculous mycobacteria, endemic fungi, and cancer.

Sudden liver or gut illness after eating shared contaminated food: think true foodborne mycotoxicosis, and involve public health and toxicology.

Vague, widespread symptoms (fatigue, brain fog, pain, poor sleep, gut trouble) with no objective findings on allergic, lung, infectious, or toxicology workup: do not default to "mycotoxin toxicity" on the strength of an unproven urine panel. Broaden the differential instead.

Step 2: Assess the Patient's Risk Factors

These questions shift the odds far more than the color of mold on a home report. How strong is the immune system? Is the patient on steroids or biologic drugs? Any history of cancer, transplant, or dangerously low white blood cells? Diabetes? Pre-existing lung disease? Asthma or allergy? Cystic fibrosis? Occupational exposures? Water intrusion at home? When did the symptoms start relative to the exposure? Any relevant travel or food history?

Step 3: Order Tests That Match the Suspected Mechanism

Treatment: Match the Treatment to the Mechanism

First Things First: Fix the Environment

Find and fix the water leak. Safely remove mold-damaged materials. This step is always appropriate, whatever the final diagnosis turns out to be. A damp building is bad for health, and that is not in dispute.

Allergic Disease

Treat allergic rhinitis and asthma with standard, guideline-based care: antihistamines, nasal steroids, inhalers. Refer to an allergist if the trigger is unclear or symptoms persist. For ABPA, the mainstays are corticosteroids and sometimes an antifungal such as itraconazole. For HP, getting the patient away from the trigger is the single most important step, with steroids and immune-suppressing drugs reserved for cases with scarring.

Fungal Infection

Use targeted antifungal drugs matched to the specific fungus and the specific infection. Some cases call for surgery to remove infected tissue. If the patient is on immune-suppressing medication, reduce it when it is safe to do so. Drug choice, treatment length, and the need for combination therapy all depend on the situation.

Clinical Pearl: Steroids that are exactly right for ABPA or HP can be disastrous in a patient with an unrecognized invasive fungal infection. That is one more reason to identify the mechanism before reaching for a treatment. It is not academic. It can be lifesaving.

What Does NOT Have Proven Value

The treatments below have no established evidence base for supposed chronic indoor mycotoxin poisoning, and several carry real risks, whether side effects, drug interactions, nutritional harm, or steep cost.

Antifungal drugs prescribed only because a home mold test was positive, because symptoms are vague, or because a urine panel read "positive." Antifungals kill living fungi. They do nothing to preformed mycotoxins.

"Binders" such as cholestyramine, activated charcoal, and bentonite clay, sold as mycotoxin detoxifiers.

Sauna protocols, colonics, and chelation marketed as "mold detox."

Long-term extreme elimination diets beyond what is nutritionally sound.

Multi-step "detox" protocols that stack several of the above.

In Plain Language: If a practitioner diagnoses "chronic mold toxicity" mainly from a urine panel and then prescribes binders, saunas, and months of antifungals without working through the evaluation in this chapter, it is reasonable to seek a second opinion. Feeling heard matters. But feeling heard is not the same as an accurate diagnosis, and an inaccurate one delays the real answer.

Red Flags: When to Get Help Immediately

Some situations call for urgent evaluation by infectious disease, pulmonary, emergency, or ear-nose-throat specialists:

Red Flag: A patient with a severely weakened immune system who develops fever, cough, chest pain, low oxygen, coughing up blood, or new findings on lung imaging.

Red Flag: A patient with very low white blood cells, a transplant, blood cancer, or prolonged high-dose steroid use who develops a matching illness.

Red Flag: Facial pain or swelling, black tissue on the nose or palate, facial nerve problems, vision changes, or severe sinus symptoms in a patient with a weakened immune system or in diabetic ketoacidosis.

Red Flag: Steadily worsening shortness of breath, widespread lung disease, respiratory distress, or significant bleeding from the lungs.

Red Flag: Jaundice (yellowing of the skin or eyes), bleeding problems, severe vomiting, or a cluster of people falling ill after eating the same contaminated food.

The Bottom Line

The most reliable way to tell these three conditions apart is to look for evidence that fits each one.

For infection: is there proof that a living fungus is growing in tissue?

For allergy: is the immune system reacting to mold in a way that matches the symptoms?

For toxicity: is there a real toxin, a real route, and a real dose that add up?

Damp buildings should always be fixed. But finding mold, or getting a "positive" urine mycotoxin result, cannot by itself tell you which of the three is happening. Confusing them leads to wrong diagnoses, wrong treatments, wasted money, and patients who still have no answers.

The way forward is not to wave off people who feel sick after mold exposure. It is to take their symptoms seriously enough to do the real work of finding the cause, through mechanism-based evaluation, evidence-based testing, and an honest conversation about what the science does and does not support.

Clinical Pearl: When a patient asks whether they have "mold toxicity," the most useful answer is not yes or no. It is, "Let's figure out exactly what's going on." That means naming the symptom pattern, weighing the patient's risk factors, ordering the right tests for the right mechanism, and treating what you actually find.

References

1. Patterson TF, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.

2. Centers for Disease Control and Prevention. Clinical Overview of Aspergillosis.

3. Centers for Disease Control and Prevention. Mold.

4. U.S. Environmental Protection Agency. Molds and Health for Public Health Professionals.

5. Raghu G, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69.

6. American College of Medical Toxicology. Medical Toxicology Considerations in the Diagnosis and Treatment of Patients with Concerns About Mold-Related Inhalation Exposures. 2025.

7. World Health Organization. Mycotoxins. WHO Fact Sheet.

8. U.S. Food and Drug Administration. Mycotoxins.

9. Centers for Disease Control and Prevention. Health Problems Related to Mold.

10. Cox L, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–S55.

11. American Academy of Allergy, Asthma & Immunology. Mold Allergy: Symptoms, Diagnosis, Treatment, and Management.

12. Hurraß J, et al. AWMF mold guideline “Medical clinical diagnostics for indoor mold exposure” — Update 2023, AWMF Register No. 161/001. Allergol Select. 2024;8:90–198. doi:10.5414/ALX02444E.

13. Kawamoto M, Page E. Use of Unvalidated Urine Mycotoxin Tests for the Clinical Diagnosis of Illness — United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(6):157–158.

14. American Academy of Allergy, Asthma & Immunology. Toxic Mold Syndrome: Separating Fact from Fiction.

15. Centers for Disease Control and Prevention. Aspergillosis (Overview).

16. Centers for Disease Control and Prevention. Aspergillosis Basics.

17. Centers for Disease Control and Prevention. Reducing Risk for Aspergillosis.

18. Denning DW, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45–68.

19. Centers for Disease Control and Prevention. Symptoms of Aspergillosis.

20. Agarwal R, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024;63(4):2400061.

21. Alberti ML, Rincon-Alvarez E, Buendia-Roldan I, Selman M. Hypersensitivity Pneumonitis: Diagnostic and Therapeutic Challenges. Front Med (Lausanne). 2021;8:718299.